vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Significant Decrease in Short Interest

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) saw a large decrease in short interest in May. As of May 15th, there was short interest totalling 16,400 shares, a decrease of 24.1% from the April 30th total of 21,600 shares. Currently, 1.1% of the company's shares are sold short. Based on an average daily trading volume, of 21,600 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on VTVT shares. Wall Street Zen started coverage on vTv Therapeutics in a report on Wednesday, April 16th. They set a "sell" rating on the stock. HC Wainwright began coverage on shares of vTv Therapeutics in a research note on Wednesday, April 9th. They set a "buy" rating and a $36.00 target price on the stock.

Institutional Trading of vTv Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. purchased a new position in shares of vTv Therapeutics during the fourth quarter worth $25,000. Connective Capital Management LLC acquired a new position in vTv Therapeutics during the 1st quarter worth about $162,000. Finally, Geode Capital Management LLC boosted its holdings in vTv Therapeutics by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after acquiring an additional 1,327 shares during the period. Hedge funds and other institutional investors own 17.51% of the company's stock.

vTv Therapeutics Price Performance

VTVT traded down $0.24 during trading hours on Tuesday, reaching $16.30. The company's stock had a trading volume of 2,472 shares, compared to its average volume of 23,278. The stock has a market cap of $52.08 million, a PE ratio of -3.60 and a beta of 0.77. vTv Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $26.99. The business's 50-day moving average is $19.20 and its 200-day moving average is $17.23.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.04).

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.